Incyte Corporation (INCY)
| Market Cap | 12.02B |
| Revenue (ttm) | 4.41B |
| Net Income (ttm) | 21.27M |
| Shares Out | 193.57M |
| EPS (ttm) | 0.10 |
| PE Ratio | 565.24 |
| Forward PE | 10.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,819,479 |
| Open | 62.39 |
| Previous Close | 62.53 |
| Day's Range | 61.90 - 62.73 |
| 52-Week Range | 52.81 - 83.95 |
| Beta | 0.69 |
| Analysts | Hold |
| Price Target | 73.06 (+17.63%) |
| Earnings Date | Apr 29, 2025 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for INCY stock is "Hold." The 12-month stock price forecast is $73.06, which is an increase of 17.63% from the latest price.
News
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). The presentat...
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Office...
Incyte raises 2025 sales forecast for blood cancer drug after solid quarter
Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025.
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO25--Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 20...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is ex...
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years...
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Incyte's skin disease drug meets main goal in two late-stage studies
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis Suppurativa.
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant regrowt...
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN).
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting.
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
WILMINGTON, Del. & BURLINGAME, Calif.--(BUSINESS WIRE)--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration.
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual Health Care Conference o...
Reevaluating Incyte Corporation After Earnings (Technical Analysis)
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below it...
Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing ...
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Ex...